Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations

scientific article published on 17 December 2018

Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1155/2018/3810108
P932PMC publication ID6311857
P698PubMed publication ID30647797

P50authorDawn QuelleQ42576515
Kimberly K LeslieQ56915077
Xiangbing MengQ59680607
Eric J DevorQ91064844
P2093author name stringShujie Yang
Shaikamjad Umesalma
Yujun Li
Kristina W Thiel
William H Thiel
Xinhao Wang
Yiyang Li
Jianling Bi
P2860cites workExtensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.Q40169580
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cellsQ40310345
Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivinQ40336893
Gain of function mutations in p53.Q41557652
Molecular sequelae of histone deacetylase inhibition in human malignant B cellsQ44280918
Synthetically lethal nanoparticles for treatment of endometrial cancer.Q47370432
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignanciesQ60200233
Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effectsQ73212118
DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA StabilizationQ24302100
MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiationQ24337242
The DNA-damage response in human biology and diseaseQ24606586
Comprehensive molecular portraits of human breast tumoursQ24630844
Thermodynamic stability of wild-type and mutant p53 core domainQ24648879
Spotlight on ixazomib: potential in the treatment of multiple myelomaQ26774440
Integrated genomic analyses of ovarian carcinomaQ27860518
The role of p53 in cancer drug resistance and targeted chemotherapyQ28072553
The DNA damage response: ten years afterQ28261230
Integrated genomic characterization of endometrial carcinomaQ28289962
Cell-cycle checkpoints and cancerQ28293996
Mutational landscape and significance across 12 major cancer typesQ28300353
ATM and related protein kinases: safeguarding genome integrityQ29547735
Chk1 and Chk2 kinases in checkpoint control and cancerQ29617706
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.Q30538161
Determination of substrate motifs for human Chk1 and hCds1/Chk2 by the oriented peptide library approach.Q30804251
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple MyelomaQ33431778
Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of functionQ33825046
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.Q33931140
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.Q34775855
The oncogenic roles of p53 mutants in mouse modelsQ36701574
Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?Q36823657
CDC25 phosphatases in cancer cells: key players? Good targets?Q36849329
Chaperone-mediated autophagy degrades mutant p53.Q37098172
Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and PanobinostatQ37199772
Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.Q37402942
Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53Q37411955
When mutants gain new powers: news from the mutant p53 field.Q37582777
A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivoQ38411451
Integrating genetic approaches into the discovery of anticancer drugsQ38555487
Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?Q38934098
Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell typesQ39748970
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P304page(s)3810108
P577publication date2018-12-17
P1433published inDisease MarkersQ15756044
P1476titleCombination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations
P478volume2018

Reverse relations

cites work (P2860)
Q90399148Pathogenesis and Clinical Management of Uterine Serous Carcinoma
Q89720874Proteogenomic Characterization of Endometrial Carcinoma
Q90093670The role of ubiquitination in tumorigenesis and targeted drug discovery
Q97524894Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer

Search more.